Dr. Patrick Baumhof is currently Vice President Formulation & Delivery at CureVac GmbH, a privately held German biopharmaceutical company which develops mRNA based Therapeutics. He received his degree in organic chemistry from the University Leipzig. After an industrial postdoc at Qiagen, he joined CureVac in 2007 as a scientist in formulations and RNA stabilization. During this time he developed several different formulations for mRNA for several different applications and works on the translation of these from pre-clinical testing to clinical testing. His research interests are formation & characterization of mRNA based nanoparticles, their biological activity after local and systemic application, and their biodistribution and efficacy in several different animal species. Dr. Baumhof joined CRS in 2009 and is looking forward to working together with others in advancing this wonderful society.
Profile: Patrick Baumhof
